Last reviewed · How we verify
Ora-Plus
At a glance
| Generic name | Ora-Plus |
|---|---|
| Also known as | Ora-Plus® |
| Sponsor | Universitaire Ziekenhuizen KU Leuven |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Periodontal Dressings in Non-Surgical Therapy (NA)
- Referral of Patients With Biological Abnormalities to an Emergency Department
- Retinal Detachment Prevention (Laser Prophylaxis) in Stickler Syndrome (SS) (NA)
- Evaluation of Two Non-Invasive Methods, High-Resolution Microendoscopy and Liquid-Based Cytology, for Detection of Oral Precancer (NA)
- Peripheral Retina Robotically Aligned OCT Study (NA)
- Topical Diclofenac vs.Oral Ibuprofen for MSK Pain in Children (PHASE3)
- Mucoadhesive Modified-Release Formulations for the Topical Treatment of Symptomatic Oral Lichen Planus (PHASE2)
- Evaluation of the Effect of Different Biomaterials on Palatal Wound Healing. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ora-Plus CI brief — competitive landscape report
- Ora-Plus updates RSS · CI watch RSS
- Universitaire Ziekenhuizen KU Leuven portfolio CI